The 2nd Due Diligence for Life Sciences Summit covers topics such as:
- Mitigating risks by evaluating new rules and regulations due to COVID-19, specifically regarding the implications associated with remote due diligence practices
- Best practice updates of due diligence prior to, during, and after a sale to monetize a product in order to reduce time wasted and maximize efficiency
- How virtual tools can affect decision making and data tracking more effective and ensure and compliance within regulatory guardrails
- How to facilitate global data sharing in a fair way that leverages the capability of information and makes manufacturing and distribution abilities more efficient
- Why organization and understanding of IP practices matters more than trying to reinvent the process
The 2nd Due Diligence for Life Sciences Summit brings together Pharmaceutical, Biotechnology professionals with responsibilities in:
- Business Development
- Due Diligence
- Mergers and Acquisitions
- Strategic Alliance/Alliance Management
- BD&L
- Licensing
- Legal and Regulatory Compliance
- General Counsel/Corporate Counsel
- Digital Partnerships
- Legal / IP
- Strategic Alliances/Partnerships
- Digital Investments
- Intellectual Property and Patent Counsel
- Management
- Search and Evaluation
- Key Accounts/Key Account Management (KAM)
- Portfolio Management
- Safety
- Search and Evaluation
- Portfolio / Life Cycle Management
- Clinical Operations
- External Innovation
- Compliance
- Regulatory Affairs
- Transactions
- Scientific Assessment
